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Background: Neutrophils have been involved in the pathogenesis of chronic obstructive pulmonary disease
(COPD). Underlying mechanisms of neutrophil accumulation in the airways of stable and exacerbated COPD
patients are poorly understood. The aim of this study was to assess exhaled breath condensate (EBC) neutrophil
chemotactic activity, the level of two chemoattractants for neutrophils (GRO-α and LTB4) during the course of an
acute exacerbation of COPD (AECOPD).
Methods: 50 ex smoking COPD patients (33 with acute exacerbation and 17 in stable disease) and 20 matched ex
smoking healthy controls were compared. EBC was collected by using a commercially available condenser
(EcoScreen®). EBC neutrophil chemotactic activity (NCA) was assessed by using Boyden microchambers.
Chemotactic index (CI) was used to evaluate cell migration. LTB4 and GROα levels were measured by a specific
enzyme immunoassay in EBC.
Results: Stable COPD and outpatients with AECOPD, but not hospitalized with AECOPD, had raised EBC NCA
compared to healthy subjects (p < 0.05 and p < 0.01 respectively). In outpatients with AECOPD EBC NCA
significantly decreased 6 weeks after the exacerbation. Overall EBC NCA was weakly correlated with sputum
neutrophil counts (r = 0.26, p < 0.05).
EBC LTB4 levels were increased in all groups of COPD compared to healthy subjects while GRO-α was only raised in
patients with AECOPD. Furthermore, EBC LTB4 and GRO-α significantly decreased after recovery of the acute
exacerbation. Increasing concentrations (0.1 to 10 μg/mL) of anti- human GRO-α monoclonal antibody had no
effect on EBC neutrophil chemotactic activity of 10 exacerbated COPD patients.
Conclusions: EBC NCA rose during acute exacerbation of COPD in ambulatory patients and decreased at recovery.
While LTB4 seems to play a role both in stable and in exacerbated phase of the disease, the role of GRO-α as a
chemotactic factor during AECOPD is not clearly established and needs further investigation.
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by airway remodelling and an inflammatory cell in-
filtrate in which neutrophils play a key role [1]. The extent
of neutrophilic infiltration in both the airway lumen and
tissues is correlated with COPD severity [2-4], is associ-
ated with bronchial colonisation [5] and forced expiratory
volume in one second (FEV1) decline in stable COPD pa-
tients [5,6] and is amplified during exacerbation [7,8].
However neutrophil accumulation mechanisms in the air-
ways are poorly understood. They could involve increased
neutrophil influx with or without increased survival of
these cells.
There has been growing interest in the use of exhaled
breath condensate (EBC) as a non-invasive method for
assessing inflammation in many lung diseases such as
COPD [9-12]. This technique has the advantage of being
particularly well tolerated by patients with an acute
exacerbation of COPD (AECOPD) [13,14]. Many bio-
markers and components can be measured or detected
in EBC, which are derived from aerosolised particles
from the whole bronchial tree (proximal and distal
airways) [9]. Some of them are chemoattractants for
neutrophils (Leukotriene B4 (LTB4), Growth related
oncogen-α (GRO-α), Interleukin-8 (IL-8)). However the
detection of IL-8 in EBC remains problematic because
its level is close to the lower limit of detection in cur-
rently available immunoassays [14-16].
On the other hand the biological activity of EBC has
been poorly investigated so far. In a previous study [17],
we found that active smoking and COPD were associated
with raised EBC neutrophil chemotactic activity (NCA),
and demonstrated the contribution of IL-8 and LTB4 to
this activity in stable disease [18].
COPD patients are characterized by periods of exacer-
bation of their illness (AECOPD) and recurrent AECOPD
contribute to the decline in lung function, decrease of
quality of life and increased morbidity and mortality [19].
Most exacerbations of COPD are due to an airway infec-
tion [19]. During bacterial AECOPD, the neutrophils and
neutrophil products (myeloperoxydase and elastase) as
well as the neutrophil chemotactic attractants (IL-8 and
LTB4) were found to temporarily increase in sputum and
EBC before returning to lower levels after treatment
[13,20-23].
The aim of this study was to assess the EBC NCA,
GRO-α and LTB4 during the course of an acute exacer-
bation of COPD.
Methods
Study design and subject characteristics
We prospectively recruited 50 ex-smoking moderate to
very severe COPD patients (17 with AECOPD leading to
hospitalisation, 16 outpatients with AECOPD and 17 instable disease) and 20 ex-smoking healthy controls. The
subgroup of COPD patients with AECOPD was longitu-
dinally followed (Figure 1). The demographic, functional
and treatment characteristics of the subjects are given in
Table 1. All the COPD patients fulfilled the criteria pro-
posed by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines [19].
Outpatients with AECOPD were recruited from the
consultations and hospitalized patients when admitted
into the ward (Department of Pneumology, CHU of
Liège). If patients were already treated with antibiotics
and/or systemic steroids at the admission in the hospital,
they were not being included in the study. AECOPD is
defined as an event in the natural course of the disease
characterized by a change in the patient’s baseline dys-
pnoea, cough and/or sputum that is beyond normal day-
to-day variations, is acute in onset, and may warrant a
change in regular medication [24,25]. Sputum was de-
fined as “purulent” when patients reported a change in
the color of spontaneously expectorated samples over
the past 72 h from uncolored to yellow-green [26]. Exac-
erbations were graded as moderate when requiring treat-
ment with systemic corticosteroids and/or antibiotics
and as severe if hospitalization or a visit to the emer-
gency department was required. They were treated ac-
cording to good clinical practice, outpatients (moderate
AECOPD) received broad spectrum antibiotics and/or
systemic steroids according to COPD severity and to
Anthonisen criteria [27]. All hospitalized patients re-
ceived systemic corticosteroids and antibiotics.
All sample collections and the measurements (EBC,
sputum culture, spirometry and induced sputum) were
performed during an exacerbation, before starting treat-
ment for outpatients, and 72 h after starting treatment
for hospitalized patients, and then repeated 6 weeks later
when patients were in a stable condition.
Healthy subjects and stable COPD attended the la-
boratory for one single visit. COPD patients were all in
stable condition at the time of EBC collection, blood
sample collection and sputum induction, and no patient
were studied within 12 weeks of any exacerbations re-
quiring change in maintenance treatment or oral steroid
and antibiotic prescription. Twenty ex-smoking subjects,
with normal pulmonary function, were also studied as
controls. They had not suffered from asthma or chronic
bronchitis.
Subjects were considered as ex-smokers if they had
stopped smoking for at least six months prior to the study.
Ex-smoking status was checked by measuring urinary co-
tinine levels.
The protocol was approved by the ethics committee
“Hospitalo-Facultaire Universitaire” of Liège (IRB: 2005/
181), and subjects gave written informed consent for
their participation.
Figure 1 Flow chart showing the study design.
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Exhaled breath condensate (EBC) was collected by using
a commercially available condenser (EcoScreen®, Erich
Jaeger Viasys GmbH, Hoechberg, Germany), according to
ATS/ERS recommendations [9], which yielded nongas-
eous components of the expiratory air. Subjects breathed
through a mouthpiece connected to the condenser. They
were asked to breathe at a normal frequency and tidal vol-
ume, wearing a nose clip, for a period of 10 min. Approxi-
mately 1.5 - 2 ml of EBC were collected and immediately
stored (in 250 μL aliquots) at 80°C, within 5 min after
collection, until analysis. All samples were tested for
salivary contamination by determination of α-amylaseconcentration (enzymatic colorimetric assay with a detec-
tion limit of 3U/mL). The collection of EBC systematically
preceded the sputum induction procedure.
Neutrophil isolation
Neutrophils were isolated using a two step procedure
from 40 ml of peripheral venous blood of the same non-
atopic and non smoking healthy volunteer. The whole
blood was treated with Geloplasma® (Institut Merieux
Belgium) 9/1, for 45 minutes to sediment the red blood
cells. The leukocytes-rich liquid phase was diluted three
times with phosphate buffer saline (PBS) and was centri-
fuged through a Percoll® separating solution (Biochrom-







No of subjects 20 17 16 17
Age (yrs) 57.1 ± 8.7 59.8 ± 7.4 61.8 ± 6.4 63.8 ± 8.4
Male/female number 8/3 13/4 13/3 13/4
BMI (kg/m2) 24.2 ± 3.3 25.8 ± 3.4 26.1 ± 4.8 26.7 ± 7.1
Number of pack years 25.2 ± 13.8 41.3 ± 18.9 † 41.4 ± 11.8 † 43.3 ± 14.3 ††
FEV1,% predicted value 99.6 ± 14.8 52.5 ± 18.0 ††† 48.1 ± 11.6 ††† 37.0 ± 14.1 †††*
FEV1/FVC% 77.5 ± 4.7 50.7 ± 11.7 ††† 47.0 ± 13.3 ††† 46.2 ± 9.5 †††
GOLD stages No
GOLD 2 11 10 4*#
GOLD 3-4 6 6 13*#
Inhaled corticosteroid
Number 13 15 14
Mean daily dose of ICSμg¶ 1235.3 ± 877.1 1421.9 ± 553.2 1588.2 ± 678.6
Long-acting B2 agonist, number 13 15 14
Long-acting Anticholinergic, number 15 14 16
Oral steroids¶¶, number 0 0 17
Data are expressed as means ± SD.
¶Expressed as beclomethasone equivalent (In converting corticosteroid drugs to a beclomethasone equivalent, we assumed that 1 mg of beclomethasone was
equivalent to 0.8 mg of budesonide, 0.5 mg of fluticasone).
¶¶Taken at the moment of sampling.
† p < 0.05, †† p <0.01, ††† p < 0.001 vs controls. *p < 0.05 vs stable COPD, #p < 0.05 vs outpatients with exacerbation of COPD.
COPD: chronic obstructive pulmonary disease; BMI: body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital capacity.
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400 g for 30 minutes at 22°C) to separate the mono-
nuclear leukocytes from the granulocyte fraction (>95%
neutrophils). Neutrophils were then washed twice in
PBS and resuspended in Hank’s balanced salt solution
(HBSS) with Ca2 + and Mg2+ (pH 7.4) and 0.2% bovine
serum albumine (BSA) at 1.106 cells.mL−1.
EBC Neutrophil chemotaxis
In this study, EBC neutrophil chemotactic activity were
assessed by using Boyden microchambers as previously
described [17,18]. Aliquots of 28 μL of EBC were placed
in the lower chambers and 50 μL of cells suspension
(106 cells.mL−1) were placed in the upper chambers. The
two chambers were separated by a polycarbonate poly-
vinylpyrrolidone (PVP) - free filter 0.8 μm Nuclepore®
(Whatman, USA). Experiments were performed in tripli-
cate in a 48-well microchemotaxis Boyden chamber
incubated in 5% C02 at 37°C for 60 min. The negative
controls consisted of a solution of HBSS with Ca2 + and
Mg2+ (pH 7.4). Chambers were dismantled and nonmi-
grated cells were scraped from the upper surface of the
filters. The filters were then immersed in methanol and
stained with Diff-Quick. Migrated cells adherent to the
lower surface were counted in 10 fields in each well at a
magnification X 600. The results were expressed as the
number of neutrophils having migrated/10 high powerfield. Chemotactic index (CI) was calculated by the ratio
of cell migration with the EBC/cell migration with
Hank’s Balanced Salt Solution (as control). A value of 1.0
representing no chemotactic activity. The optimal con-
centration of EBC that was used in chemotaxis assays
was determined previously and was 1/1 of the original
sample [17,18]. The reproducibility of repeat EBC neu-
trophil chemotactic activity measurements was assessed.
The intraclass correlation coefficient and the Spearman
correlation coefficient were 0.67 and 0.74 (p < 0.01) re-
spectively [17].
Sputum induction and processing
Sputum induction and processing were performed accord-
ing to a technique used in routine in our service [28], and
a differential leukocyte count was obtained using a cytos-
pin stained with May-Grünwald Giemsa on 500 non squa-
mous cells. A bacteriological analysis of induced sputum
was also carried out for exacerbated COPD patients.
Peripheral blood puncture and assessment of systemic
inflammation
Venous blood was collected in Vacutainer tubes from an
antecubital site immediately when controls and patients
were included in the study. Blood cell values included
hemoglobin, platelet count, WBC count, and the
differential leukocyte count, fibrinogen and C-reactive
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routine of the hospital.
GRO-α and LTB4 measurements in EBC
LTB4 and GRO- α were measured by a specific enzyme
immunoassay with a commercial kits (LTB4 : Cayman
Chemical Company, Ann Arbor, Michigan, USA; GRO-α:
R&D Systems Europe, Abingdon, UK) according to in-
structions provided by the manufacturer. Immunoassay
detection limits were 13 pg/mL and 15.6 pg/mL for LTB4
and GRO-α respectively. The intra-assay and inter-assay
variabilities of LTB4 and GRO-α were less than 10%.
Determination of the contribution of GRO-α to EBC
neutrophil chemotaxis
First, solutions of GRO-α at increasing concentrations
(0.0126 to 126 nM) were added in the lower part of Boy-
den microchambers, while suspensions of neutrophils
were added in the upper part to study neutrophil CI.
Maximal stimulating concentration was 12.6 nM, the
NCI was 4.5 ± 1.3 and significantly different from 1
(p < 0.05).
We also validated our anti-human GRO-α monoclonal
antibody (Human CXCL1/GRO-α antibody (R&D Sys-
tems, Abingdon, UK)) by looking for the maximal inhibit-
ing concentration on NCA induced by GRO-α at 12.6
nM. The maximal inhibiting concentration was 0.1 μg/ml
(−48.2%). Thereafter, serial concentrations (0.1 μg/ml to
10 μg/ml) of anti-human GRO-α monoclonal antibody
were added to EBC for 1 h at room temperature before
assessing EBC chemotactic activities.
Statistical analysis
Demographic and functional data were expressed as
mean ± standard deviation (SD). EBC LTB4 and GRO-α
levels, induced sputum cellularity and EBC neutrophil
CI were expressed as median and interquartile range
(IQR). When the data showed normal distribution, they
were compared with a one-way ANOVA, followed by
Tukey-Kramer’s post-hoc testing. When the data did
not show a normal distribution, they were compared
with the Kruskal-Wallis test followed by Dunn’s post-
hoc testing. Comparison between the stable phase and
the exacerbation phase were performed with a paired t-
test or Wilcoxon test according to the normality of the
distribution. CI for each group of samples was evaluated
by one-sample “t” test versus a hypothetical mean of 1.0
(representing zero net chemotactic activity). Levels of
measured mediators below the detection limit of the
ELISA kits were arbitrarily assumed to be half of the
detection limit value for statistical analysis. Correlations
between variables were performed using Spearman’s
rank correlation test. A p < 0.05 was considered as
significant.Results
Demographic, functional and microbiologic characteristics
of subjects
Healthy ex-smokers, as well as ex-smoking COPD patients
with stable disease or exacerbation were well matched for
age, gender and BMI (Table 1). As expected, COPD pa-
tients exhibited a poorer lung function and a more import-
ant cumulative tobacco smoke exposure compared to
healthy ex-smokers. Moreover, hospitalized patients were
more severely limited as shown by a higher proportion of
GOLD stage 3–4 (13/17 patients) compared to the two
other groups of COPD (6/17 for stable and 6/16 for outpa-
tients with AECOPD, both comparisons with p < 0.05).
Among the 17 patients hospitalized for AECOPD only
11 were analyzed at 6 weeks for the recovery: 2 patients
had another exacerbation before the control visit and were
excluded from the study and 4 did not come at the control
visit. By contrast, all outpatients with AECOPD attended
their control visit at 6 weeks.
Among outpatients with AECOPD, 8 on 16 had a positive
sputum bacterial culture (4 streptococcus pneumoniae, 1
Haemophilus influenzae, 2 Pseudomonas aeruginosa and 1
Moraxella catarrhalis), while the culture was positive in 9 on
17 hospitalized AECOPD (2 streptococcus pneumoniae, 3
Haemophilus influenzae, 1 Moraxella catarrhalis, 1 Escheri-
chia coli and 2 Pseudomonas aeruginosa).
Airway and blood neutrophilic inflammation in COPD
COPD was clearly characterized by an intense airway
neutrophilic inflammation compared to healthy subjects
(Table 2, Figure 2). Neutrophilic inflammation was further
increased during exacerbation but this did not reach
statistical significance. At blood level, exacerbated COPD
displayed raised total leukocyte counts and a raised propor-
tion of neutrophils (Figure 3). The levels of fibrinogen and
CRP were also higher in blood of AECOPD patients com-
pared to stable COPD patients and healthy subjects
(Table 2). There was clear clinical improvement in patients
6 weeks after exacerbation as reflected by better spirometric
indices and reduction in neutrophilic inflammation (Table 3
and Figure 4). We found a fall in mean blood neutrophils
count of 4669/mm3 (95% Confidence Interval: 915–8424)
and 2221/mm3 (95% Confidence Interval: 537–3906), and a
fall in mean CRP of 24.05 mg/L (95% Confidence Interval:
1.36 - 46.73) and 43.46 mg/L (95% Confidence Interval:
13.76-72.97) respectively for hospitalized and outpatients
with AECOPD.
EBC Neutrophil chemotactic activity
EBC NCA from stable COPD, outpatients with AECOPD,
hospitalized patients with AECOPD and healthy subjects
displayed all significant neutrophil NCA (median (IQR) CI
(chemotactic index): 2.3 (0.7) p < 0.0001; CI: 2.9 (1.5) p <
0.01, CI: 1.8 (1.8) p < 0.01 and CI 1.0 (1.4), p < 0.05







No of subjects 20 17 16 17
Blood
Leukocytes (per mL) 5530 (3060) 7825 1420) 8825 (5040)* 12660 (5430)**†
Neutrophils (per mL) 3295 (1940) 4985 (1560) 6670 (5093)** 9090 (6030)**†
% neutrophils 60.1 (7.8) 59.2 (7.6) 76.0 (8.4)**†† 84 (15.2)**†††
% lymphocytes 30.9 (7.3) 28.9 (8.6) 17.0 (10.1)* 10.8 (8.3)**†††
CRP (mg/L) 0.9 (2.1) 3.9 (5.9) 21.4 (83.5)**† 9.2 (49.0)**†
Fibrinogen (g/L) 2.6 (0.6) 3.3 (1.4) 4.9 (2.4)***††† 5.1 (1.7)***†
Induced sputum
Squamous epithelial cells (%) 24.0 (25.0) 10.0 (10.0) 0.0 (2.0)** 6.0 (21.0)
Total non squamous cell count (x106 cells/g sputum) 0.3 (1.2) 3.7 (6.4)* 13.1 (25.7)** 6.0 (16.5)**
Viability (%) 69.5 (24.8) 78 (16) 86.5 (14.5) 72.5 (29.5)
Neutrophils, % 49.3 (36.1) 81.5 (28.5)* 91.0 (7.6)** 83.5 (25.3)*
Neutrophils count(x103/g sputum) 120.2 (532) 4511.8 (5853)* 11139.0 (24009)** 3523.8 (16974)**
Macrophages, % 32.0 (26.1) 8 (14.7)* 4.5 (7.1)** 6.5 (10.9)**
Eosinophils, % 0.0 (0.6) 2.5 (3.8)* 0.4 (0.6) 0.5 (1)
Lymphocytes, % 1.9 (2.6) 1.0 (1.8) 1.0 (1.0) 1.3
(2.8)
Epithelial cells, % 6.8 (21.8) 7.0 (7.9) 1.8 (3.6) 1.1 (7.9)
Exhaled breath condensate
LTB4 pg/mL 34.0 (28) 74.0 (53)* 66.0 (47.0)** 68 (46)*
GRO-α pg/mL 10.0 (13) 17 (34) 56.1 (49.0)* 45.0 (46.0)*
Data are expressed as medians (IQR), or mean cells counts are expressed as absolute counts per gramme (g) of sputum and as percentages of total inflammatory
cells, excluding squamous cells. COPD: chronic obstructive pulmonary disease.
*p < 0.05, **p < 0.001, ***p <0.0001 vs healthy subjects, †p <0.05, †† p <0.01, ††† p <0.001 vs stable COPD.
Figure 2 Sputum neutrophil counts from stable and exacerbated
COPD patients and healthy ex-smokers subjects. Horizontal bars
represent the median. SCS-AB: treatment with antibiotics and systemic
corticosteroids before EBC collection.
Figure 3 Blood neutrophil counts from stable and exacerbated
COPD patients and healthy ex-smokers subjects. Horizontal bars
represent the median. SCS-AB: treatment with antibiotics and systemic
corticosteroids before EBC collection.
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Table 3 Changes in functional parameters, blood cells and markers of inflammation, induced sputum cells, EBC LTB4
and GRO-α during an acute exacerbation phase and a stable phase of COPD
Outpatients (n = 16) Hospitalized patients (n = 11)
Exacerbated phase Stable phase Exacerbated phase Stable phase
Functional parameters
FEV1, % predicted 48.1 ± 2.9 56.8 ± 3.4**** 36.1 ± 4.6 42.7 ± 5.9*
FEV1/FVC % 47.0 ± 3.3 49.0 ± 3.5 47.9 ± 2.6 49.7 ± 2.6
Blood
Leukocytes (per mL) 8825 (5040) 7045 (1862)* 12660 (5560) 8960 (4550)**
Neutrophils (per mL) 6670 (5093) 4545 (2668)* 9090 (5485) 5890 (3720)**
Neutrophils, % 76.0 (8.4) 64.4 (23.0)**** 85.3 (14.8) 68.5 (11.0)**
Lymphocytes, % 17.0 (10.1) 23.6 (20.5)* 9.6 (8.5) 18.2 (5.7)*
CRP (mg/L) 21.4 (83.5) 1.8 (2.0)*** 8.0 (52.4) 5.5 (6.0)*
Fibrinogen (g/L) 5.5 ± 0.5 3.4 ± 0.3*** 4.7 ± 0.4 4.4 ± 0.4
Induced sputum
Squamous epithelial cells (%) 0.0 (2.0) 6.5 (9.5) 10.0 (1.0) 23.0 (4.0)
Total non squamous cell count (x 106 cells/g sputum) 13.1 (25.7) 7.2 (8.8) 5.4 (16.3) 3.7 (6.2)*
Neutrophils, % 91.0 (7.6) 81.1 (28.9)** 82.0 (24.6) 80.0 (19.5)
Neutrophils count(x103/g sputum) 11139.0 (24009.0) 4688.0 (6655.0)* 2107.4 (15597.0) 2332.8 (4304.0)
Macrophages, % 4.5 (7.1) 7.8 (14.0) 10.0 (11) 8.5 (9)
Eosinophils, % 0.4 (0.6) 1.0 (1.7) 0.5 (3.9) 1.0 (9.8)
Lymphocytes, % 1.0 (1.0) 2.0 (5.2) 1.5 (2.5) 1.5 (1.9)
Exhaled breath condensate
LTB4 pg/mL 66.0 (47) 47.0 (29.0)** 67.0 (36.0) 47.0 (30.0)
GRO alpha pg/mL 56.1 (49.0) 31.0 (29.0)** 45.0 (46.0) 15.1 (17.0)*
Functional data are expressed as means ± SD. Blood, sputum and EBC data are expressed as medians (IQR). *p < 0.05; ** p < 0.01, ***p < 0.005, **** p < 0.001.
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neutrophil counts (r = 0.26, p < 0.05).
Stable COPD and outpatients with AECOPD, but not
hospitalized COPD patients, had raised EBC NCA com-
pared to healthy subjects (p < 0.05 and p < 0.01 respect-
ively) (Figure 5).
In outpatients with AECOPD there was a significant
fall in EBC NCA after recovery (p < 0.05) (Figure 6), a
phenomenon not observed in hospitalized AECOPD
(p = 0.27).
In exacerbated outpatients and hospitalized COPD
patients, there were no significant difference in EBC
NCA between patients with or without a positive spu-
tum bacterial culture (p = 0.16 and p = 0.14 respect-
ively). Likewise there was no significant difference in
EBC NCA between those with or without purulent spu-
tum. Moreover, in outpatients with AECOPD, EBC
NCA at day 1 and day 42 were not different between pa-
tients treated or not treated by systemic steroids for
their AECOPD (p =0.92 and p =0.43 respectively).LTB4 and GRO-α values in exhaled breath condensate
We found a significant increase of LTB4 level in EBC from
stable COPD and exacerbated patients by comparison to
healthy controls (Table 2). The detection rate of EBC
LTB4 was higher (p < 0.05) in outpatients and hospitalised
patients with AECOPD (100% in both circumstance) by
comparison with controls (70%), but not with stable
COPD patients (94%). After recovery of the AECOPD,
levels of EBC LTB4 significantly fell by comparison to the
acute phase in outpatients (Table 3) and tended to do so
for hospitalized patients. There was a fall in mean EBC
LTB4 levels of 9 pg/mL (95% Confidence Interval:-12 - 30)
and 35 pg/mL (95% Confidence Interval: 11 – 60) for hos-
pitalized and outpatients with AECOPD respectively.
Compared to healthy subjects EBC GRO-α level was
only increased during exacerbation of COPD (Table 2)
whereas there was no difference between stable COPD
and healthy controls. The detection rate of EBC GRO-α
was higher (p < 0.001) in outpatients and hospitalised pa-
tients with AECOPD (75% and 82% respectively) by
Figure 4 Sputum neutrophil counts in acute phase (V1) and stable phase (V2) of outpatients and hospitalized patients with acute
exacerbation of COPD.
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and 53% respectively). At recovery, EBC GRO-α level sig-
nificantly fell in both groups of AECOPD (Table 3). We
found a fall in mean EBC GRO-α level of 29 pg/mL (95%
Confidence Interval: 14–73) and 22 pg/mL (95% Confi-
dence Interval: 7– 37) for hospitalized and outpatients
with AECOPD respectively.Correlation of EBC chemokines with EBC NCA and
sputum cells
For the whole population, there was a weak positive correl-
ation between EBC LTB4 level and both sputum neutrophil
counts (r = 0.43, p < 0.001) and EBC NCA (r = 0.34, p <
0.01). There was also a weak positive correlation between
EBC GRO-α and EBC NCA (r = 0.31, p < 0.05).Figure 5 EBC neutrophil chemotactic activity from stable and
exacerbated COPD patients and healthy ex-smokers subjects.
Horizontal bars represent the median. SCS-AB: treatment with antibiotics
and systemic corticosteroids before EBC collection.Determination of the contribution of GRO-α to EBC
neutrophil chemotaxis
Increasing concentrations (0.1 to 10 μg/mL) of our anti-
human GRO-α monoclonal antibody had no effect on
EBC neutrophil chemotactic activity of exacerbated COPD
patients (n = 10) (data not shown).
Discussion
In this study, we have clearly confirmed that EBC from
ex-smoking COPD patients contained raised neutrophil
chemotactic activity as compared to healthy ex-smokers.
The new finding is that the EBC neutrophil chemotactic
activity further increased during exacerbation but only
in those patients not already treated by antibiotics and
systemic steroids at the time of EBC collection. The
EBC neutrophil chemotactic activity for the whole popu-
lation was weakly correlated to sputum neutrophil count
and to EBC LTB4 and GRO-α levels. Furthermore, the
latter two neutrophil chemotactic agents were found to
be increased in EBC during AECOPD when compared
to healthy controls, while significantly decreasing at re-
covery time.
EBC from ex-smoking healthy subjects and COPD
patients contain active soluble chemoattractants for
neutrophils as demonstrated by a significant neutrophil
chemotactic activity. Previous studies have shown a
neutrophil chemotactic activity in the EBC of healthy
subjects [17,18,29] and COPD patients [17,18]. In
addition cigarette smoking by itself was also found to
increase neutrophil chemotactic activity [17,29]. Thus,
to be independent of the tobacco influence, we decided
in this study to work only with ex-smokers. As a result,
we confirm that EBC from stable COPD patients display
greater neutrophil chemotactic activity than those from
healthy controls. In spite of some overlapping of the
data between exacerbated and stable phase which pre-
vent us to draw strong conclusions, we showed, for the
first time, an increase in EBC neutrophil chemotactic
Figure 6 EBC neutrophil chemotactic activity in acute phase (V1) and stable phase (V2) of outpatients and hospitalized patients with
acute exacerbation of COPD.
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when compared to the recovery period. Our findings are
in keeping with the fact that neutrophilic airways inflam-
mation is indeed a major feature of COPD both in stable
phase [1,4,30-32] and during exacerbation where neutro-
phils are even more attracted into the airways [6,8,33,34].
This obviously does not exclude that some COPD patients
may have raised sputum eosinophilia but the proportion
of these patients is less than 20% both in stable phase and
during exacerbation in our study.
If the majority of the patients were clinically improved
by treatment with antibiotics and/or steroids, it doesn’t
mean that they had all an infectious exacerbation, keeping
in mind that positive culture could be also the conse-
quence of a bronchial colonization, and that a negative
culture cannot exclude an infectious exacerbation due to
viral infection. Our intention was to focus on exacerbation
whichever its trigger. It was also shown that neutrophil in-
flammatory markers declined to pre-exacerbation levels
after treatment [35-37]. It is well known that inflammation
is amplified during exacerbations. Sputum markers of air-
way neutrophilic inflammation (myeloperoxidase, neutro-
phil elastase, IL-8, LTB4) were shown to increase during
acute COPD exacerbation [21,35-38]. It was also shown
that neutrophil inflammatory markers declined to pre-
exacerbation levels after treatment [35-37].
Moreover, EBC markers of inflammation such as LTB4
[13,23] several cytokines including TNF-α, IL1-B,IL-6
and IL-8 [9,39], as well as markers of oxidative stress like
isoprostane [13,23,40] and hydrogen peroxide [23,41,42]
were also found to rise during exacerbation while dimin-
ishing following treatment or when returned to stable
phase [13,14,23,41,42].
Indeed LTB4 is a potent chemoattractant of neutro-
phils, and it may be released by macrophages, epithelial
cells and activated neutrophils [43]. Whereas EBC and
sputum represent different airway compartment, LTB4
was found to be raised in EBC [13,18,44,45] or sputum
[18,44] of stable COPD, and further increased duringexacerbations while diminishing following antibiotic
treatment [13,21,23]. Our study confirmed these results
in stable and exacerbated COPD patients. However in
hospitalized COPD patients treated by systemic cortico-
steroid and antibiotics for 3 days before EBC collection
there was no significant fall at 6 weeks after treatment.
The lack of difference between EBC LTB4 level and
NCA during hospitalization and at 6 weeks is likely to
be secondary to the anti-inflammatory effect of the treat-
ment already given at hospital before EBC collection.
This is in agreement with the study of Ko et al. [14]
where changes in inflammatory mediators including
LTB4 were not apparent during the course of AECOPD
leading to hospitalization when day 5 and 60 were con-
sidered. The time point at which sample is collected dur-
ing an exacerbation seems to be critical. Our results
suggest that the increased neutrophil chemotactic activ-
ity during exacerbation might be partly due to elevated
LTB4, although experiments with selective LTB4 recep-
tor antagonists are required.
In our study, we demonstrated for the first time that
GRO-α, a CXC chemokine with strong activating and
chemotactic abilities for neutrophils, was found to be raised
in the EBC from exacerbated, but not stable, COPD
patients. It would suggest a role of this chemokine in the
recruitment and activation of neutrophils during an
AECOPD. A previous study showed an increased of GRO-
α in sputum, but not in bronchoalveolar lavage fluid, of
stable smoking COPD patients by comparison with smok-
ing and non smoking healthy controls [46]. However, it is
admitted that EBC and sputum reflect different airway
compartments. Moreover, a recent study has demonstrated
that GRO-α could be detected in EBC of COPD and
healthy subjects, and that EBC GRO-α level is lower in
stable ex-smoking COPD by comparison with controls
[47]. In the same study, the authors did not find any differ-
ence of EBC GRO-α level between COPD patients with
and without inhaled corticosteroid therapy [47]. They, how-
ever, did not measure how GRO-a level varied during an
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a mediator essentially involved in the rise of neutrophilic
inflammation during an exacerbation, we didn’t find any ef-
fect of our anti-human GRO-α monoclonal antibody on
EBC neutrophil chemotactic activity of exacerbated COPD
patients. We could explain this discrepancy by instability of
neutrophil membranair expression of CXCR2 (ligands are
GRO-α and IL8) and CXCR1 (ligand is IL8) [48], and that
there is evidence for a functional distinction between poly-
morphonuclear neutrophil CXCR1 and CXCR2 in inflam-
matory conditions [49]. In addition, EBC, by contrast to a
pure solution of GRO-α, is a soap of chemoattractants
some of which like IL-8 may actually modulate CXCR1/2
expression [47] and thereby the neutrophil response to a
chemoattractant. Of course we cannot rule out the possibil-
ity that GRO-α, though being a potent agent in a simple
in vitro model, might only marginally contribute to the
overall chemotactic activity contained in a complex mixture
like EBC. Beside EBC there are today new omics techniques
available [50] including nuclear magnetic resonance spec-
troscopy of EBC [51-53] and electronic noses [54] that can
be used for more complete assessment of respiratory in-
flammation in stable and exacerbated COPD.
Conclusion
This study has shown that EBC from ex-smoking COPD
contained raised neutrophil chemotactic activity as com-
pared to healthy ex-smokers, with a further amplification
during exacerbation of patient not already treated by
antibiotic and systemic steroids. Furthermore LTB4 and
GRO-α, two neutrophil chemotactic agents, were found
to be increased in EBC during AECOPD while signifi-
cantly decreased at recovery time.
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